Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label perioperative SHR-8068 + adebrelimab + apatinib in resectable hepatocellular carcinoma with intermediate/high recurrence risk
CTR20262512Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002, adebrelimab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jul 2026; status: active.
02
Drugs
CS1002adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20262512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262512.